Innovative Implantable System Regulates Blood Pressure Post-Spinal Cord Injury

A groundbreaking implantable neurostimulation device has demonstrated its potential to restore healthy blood pressure levels in individuals with spinal cord injuries (SCI). Developed through a collaborative effort involving the University of Calgary, EPFL, UNIL, and Dutch research centers, this innovative system offers new hope for managing autonomic dysreflexia and blood pressure instability often experienced after SCI. The device comprises custom-designed electrode arrays connected to a compact pulse generator, similar to a cardiac pacemaker, which delivers precisely calibrated electrical stimulation tailored to each patient's needs. Controlled conveniently via a mobile app, this technology has been tested in a series of clinical trials involving 14 participants across multiple countries, including Canada, Switzerland, and the Netherlands.

The clinical studies, published in reputable journals such as Nature and Nature Medicine, reveal that once activated, the system quickly restores blood pressure to functional ranges, often within minutes. Participants, including Cody Krebs—a 32-year-old who suffered a severe SCI in 2022—have reported fewer episodes of blood pressure drops and spikes, resulting in increased energy, clearer thinking, and improved overall quality of life. The device’s safety and efficacy across diverse clinical settings underscore its potential for widespread use.

This approach addresses a long-standing challenge in SCI care—chronic hypotension and blood pressure fluctuations—that significantly impair daily functioning and elevate cardiovascular risk over time. The implantable system, manufactured by ONWARD Medical, has recently gained FDA approval to begin a pivotal trial involving numerous neurorehabilitation centers in North America and Europe. Experts highlight that, given the safety profile of similar implants used for pain management, this therapy could become a standard treatment option, providing sustained hemodynamic stability and improving life quality for those affected by SCI.

The promising results mark a significant advancement in neurotechnology, bridging foundational neuronal research and clinical application. As research progresses, this innovation could revolutionize the management of autonomic dysreflexia and related complications, making a substantial impact on SCI patient care.